Results 11 to 20 of about 174,870 (205)

Diagnosis and Treatment of Pneumocystis Carinii Pneumonia (PCP)/ Pneumocystis Jirovecii Pneumonia in HIV patient: A Case Report [PDF]

Jurnal Penyakit Dalam Indonesia, 2017
Pneumocystis carinii pneumonia (PCP) or pneumocystis jirovecii pneumonia is an opportunistic infection that can occur in immunocompromised patients. In patients with HIV, PCP is the most common opportunistic infection especially in patients with CD4 cell
Dewi Rizki Agustina, Christy Efiyanti, Evy Yunihastuti, Anna Ujainah, Anna Rozaliyani   +4 more
doaj   +4 more sources

Prognostic Score for Pneumocystis carinii Pneumonia

Respiration, 2009
Sixty episodes of Pneumocystis carinii pneumonia in 59 patients were evaluated for risk factors predicting fatal outcome within 14 days after bronchoscopy. We found significantly higher values for serum lactate dehydrogenase (p < 0.001), alveolar-arterial oxygen difference (p < 0.001) and percentage of bronchoalveolar lavage neutrophils (p < 0.
Speich, R, Weber, R, Kronauer, C M, Opravil, M, Lüthy, R, Russi, E W   +5 more
openaire   +4 more sources

Increased dosage of infliximab is a potential cause of Pneumocystis carinii pneumonia. [PDF]

Gut Pathog, 2016
http://creativecommons.org/licenses/by/4.0/METHODS: Pneumocystis carinii pneumonia occasionally appears in immunodeficient patients. While several reports have shown that Pneumocystis carinii pneumonia occurred in the early phase of starting infliximab ...
Iwama T, Sakatani A, Fujiya M, Tanaka K, Fujibayashi S, Nomura Y, Ueno N, Kashima S, Gotoh T, Sasajima J, Moriichi K, Ikuta K.   +11 more
europepmc   +2 more sources

Chitinases in Pneumocystis carinii pneumonia. [PDF]

Med Microbiol Immunol, 2012
Pneumocystis pneumonia remains an important complication of immune suppression. The cell wall of Pneumocystis has been demonstrated to potently stimulate host inflammatory responses, with most studies focusing on β-glucan components of the Pneumocystis cell wall.
Villegas LR, Kottom TJ, Limper AH.
europepmc   +4 more sources

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy [PDF]

, 2001
Background: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P.
H. Furrer, Uberti-Foppa, C., Pradier, C., Bickel, M, Monforte, A D´Arminio, Bickel, M., M. M. E. Schneider, Uberti-Foppa, C, O. Kirk, Furrer, H, Kirk, O., Schneider, M. M., Kirk, O, Lundgren, Jens Dilling, Ledergerber, B., Mocroft, A., Ledergerber, B, Lundgren, J.D., M. Bickel, P. Reiss, Lundgren, J. D., d'Arminio Monforte, A., Pradier, C, A. d'Arminio Monforte, Lederberger, B., Furrer, H., Reiss, P, Schneider, MM, A. Mocroft, for eight European HIV Cohorts, B. Ledergerber, C. Pradier, J. D. Lundgren, Schneider, M.M.E., Mocroft, A, Reiss, P., C. Uberti Foppa   +36 more
core   +2 more sources

Pneumocystis carinii pneumonia and reticuloses [PDF]

Thorax, 1968
Three cases of Pneumocystis carinii pneumonia occurring in the course of diseases of the lymphoreticular system are described. One case was diagnosed in life and unsuccessfully treated with pentamidine isethionate. Incidence of the pneumonia is associated with a depressed immune response and may be more frequent than is usually realized in patients ...
K R, Humphries, H, Ngan, K, James
openaire   +2 more sources

Increasing Pneumocystis pneumonia, England, UK, 2000-2010. [PDF]

, 2013
After an increase in the number of reported cases of Pneumocystis jirovecii pneumonia in England, we investigated data from 2000-2010 to verify the increase. We analyzed national databases for microbiological and clinical diagnoses of P.
Nichols, Gordon, Katherine L. Henderson, Nick Phin, Maini, Rishma, Delpech, Valerie, Gordon Nichols, Valerie Delpech, Rishma Maini, Phin, Nick, Theresa Lamagni, Henderson, Katherine L, Elizabeth A. Sheridan, Lamagni, Theresa, Sheridan, Elizabeth A   +13 more
core   +1 more source

Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance [PDF]

, 2004
Pneumocystis pneumonia (PCP) remains a major cause of illness and death in HIV-infected persons. Sulfa drugs, trimethoprim-sulfamethoxazole (TMP-SMX) and dapsone are mainstays of PCP treatment and prophylaxis.
Meja Rabodonirina, Chiara Atzori, Benfield, T, Helweg-Larsen, J, Rabodonirina, Meja, Robert Miller, Crothers, KA, Thomas Benfield, Huang, Laurence, Atzori, C, Rabodonirina, M, Laurence Huang, Kristina Crothers, Miller, R, Haung, L, Helweg-Larsen, Jannik, Jannik Helweg-Larsen, Miller, Robert, Crothers, Kristina, Benfield, Thomas, Atzori, Chiara   +20 more
core   +1 more source

Genotypic variation in Pneumocystis jirovecii isolates in Britain [PDF]

, 2005
Background: Pneumocystis jirovecii is the cause of Pneumocystis pneumonia (PCP) in immunosuppressed humans. Asymptomatic colonisation with P jirovecii may occur in patients with minor immunosuppression or chronic lung disease.
Davies, RJ, Wakefield, AE, Ambrose, HE, Copas, A, Lindley, AR, Miller, RF, Davies, RJO   +6 more
core   +1 more source

Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy [PDF]

, 2006
Background: Despite a decline in incidence of Pneumocystis jirovecii pneumonia (PCP), severe PCP continues to be a common cause of admission to the intensive care unit (ICU) where mortality remains high. A study was undertaken to examine the outcome from
Singer, M, Copas, A, Edwards, SG, Miller, RF, Allen, E   +4 more
core   +1 more source